Clinical Trial

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor. This open label, randomized, phase 2 study aims to evaluate the efficacy of Chidamide+Decitabine plus Anti-PD-1 Antibody and Brentuximab Vedotin plus Anti-PD-1 Antibody in transplant-ineligible or refused transplant diagnosedR/R cHL. The primary objective of the study is to evaluate progression-free survival.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-28; most recent amendment 2025-12-28.
Status change: Not Yet Recruiting → Recruiting 2024-06-09
Trial Details
NCT Number NCT06393361
Lead Sponsor Chinese PLA General Hospital
Conditions Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Enrollment 100 participants
Start Date 2024-06-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-02